All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Exempt, with results | 2008-003967-37 | Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease | 2012-12-10 | not-yet-due |
Exempt, with results | 2008-007785-39 | Safety and efficacy phase I/IIa trial of an RNActive®-derived cancer vaccine in stage IIIB/IV non small cell lung cancer (NSCLC) | 2014-02-25 | not-yet-due |
Exempt, with results Terminated | 2011-006314-14 | A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Pros... | 2017-01-19 | not-yet-due |
Completed, but no date, and reported results Terminated | 2013-004489-32 | An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer Eine unverblindete, randomisierte Phase-II-Studie mit R... | bad-data | |
Listed as ongoing, but also has a completion date and reported results | 2020-003998-22 | COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Y... | 2022-06-03 | bad-data |
Reported results | 2020-004066-19 | COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Wor... | 2022-06-08 | due-trials |
Reported results | 2020-004070-22 | COVID-19: A Phase 3 multicenter clinical trial to evaluate the safety, reactogenicity and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and above with ... | 2021-09-21 | due-trials |